Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

November 30, 2025

Conditions

Effect of Drug

Interventions

DRUG

Docetaxel

Docetaxel 75mg/m2; q21

DRUG

Pembrolizumab

Pembrolizumab 200mg, q21

Trial Locations (1)

Hokkaido University Hospital, Sapporo

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Hokkaido University Hospital

OTHER